Johnson & Johnson’s CARVYKTI Growth Slows to 57.4%, Pressures Valuation
ABBV•CARVYKTI posted approximately $600 million in quarterly sales, marking a year-over-year growth rate of 57.4%, down from 63.2% in the prior quarter. The stock trades at a price-to-sales multiple of 5.9, close to its 10-year high of 6.1, heightening risk if CARVYKTI’s growth rate continues to slow.
1. CARVYKTI Sales Performance
CARVYKTI’s quarterly sales reached approximately $600 million, reflecting a 57.4% year-over-year growth rate versus 63.2% in the previous quarter. The slight deceleration marks the first slowdown in the drug’s launch trajectory and warrants scrutiny for future momentum.
2. Growth Narrative Reliance
Johnson & Johnson has forecast $100 billion in annual revenue and double-digit growth by decade’s end, relying heavily on new therapies. CARVYKTI’s performance is a linchpin in this plan, placing added pressure on the broader oncology pipeline to drive sustained expansion.
3. Valuation Pressure
The stock’s price-to-sales multiple of 5.9 sits near its 10-year high of 6.1, suggesting elevated expectations for CARVYKTI and other new products. Any further tapering in growth could prompt valuation adjustments if pipeline outputs fall short of premium pricing assumptions.
